Danish company Novo Nordisk, the maker of Ozempic and Wegovy, had already announced headline results from the study in August last year, saying that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in overweight or obese adults in the trial
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP)
Other Side Effects Ozempic has been seen to raise the risk for other serious medical issues, including biliary diseases, and there is a suspected link between Ozempic use and pancreatic cancer
Semaglutide Safety and Monitoring Regular monitoring by healthcare professionals is vital to adjust semaglutide dosing and ensure efficacy and safety
This review provides a comprehensive overview of the mechanistic insights into the effects of GLP-1RAs and dual or triple receptor agonists on the pathophysiology of MASLD, with a focus on hepatic lipid metabolism, inflammatory responses, and fibrosis progression
The results from the second semaglutide 7.2 mg phase III trial, STEP UP T2D, in adults with type 2 diabetes and obesity are expected within the next few months
